CClinicalTrials.gg
Not yet recruitingNCT06000605BSSUpdated Aug 24, 2023

Brain Substrate Switch to Ketones and Lactate

An interventional study of Fed and Fasted in Metabolic Diseases and Aging Problems, sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by University of British Columbia · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
19 Years to 40 Years
Sex
All
01

Study summary

The brain is constantly active and energetically expensive, making up a quarter of the body's energy budget despite occupying only 2% of its mass. To fuel this incessant activity, the brain relies on glucose, which accommodates 99% of its metabolic needs. In most cases, glucose is the ideal fuel since it is in constant surplus owing to 24-hr access to sugar-rich food. However, the brain is metabolically flexible and capable of metabolizing alternative fuels when glucose is scarce, or, decreasing rapidly. For example, during fasting when glucose stores are dwindling, ketone bodies can supplement the brain's metabolic needs. During intense exercise, when glucose stores are being rapidly depleted, lactate - a byproduct of this glucose turnover - similarly acts as an alternative fuel for the brain. In healthy individuals, exploiting this 'brain metabolic flexibility' may be beneficial in protecting the brain from aging.

The main question is: Does the brain substrate switch that occurs during fasting and high-intensity exercise underlie the beneficial effects on the brain?

Young, healthy participants will fast for 3 days and complete high-intensity cycling exercise, each of which will induce a brain substrate switch. Participants will also be passively infused with ketones (to simulate fasting) and lactate (to simulate high-intensity exercise) in the fed and rested state. In doing so, the investigators will isolate the brain substrate switch from the broader, pluripotent stressors that encompass fasting and exercise.

The main outcome variables are the brain biomarkers: brain-derived neurotrophic factor (BDNF) and secreted amyloid beta precursor protein (sAPPA).

Read the detailed description

Objectives:

Primary:

  • To determine if brain ketone and lactate metabolism cause the beneficial neurotrophic responses associated with fasting and exercise, respectively.

Secondary:

  • To determine if fasting and exercise improve the brain's uptake of glucose, ketones and lactate.

Endpoints:

Primary:

  • Brain-derived neurotrophic factor (BDNF)
  • Secreted amyloid-beta precursor protein-alpha (sAPPA)

Secondary:

  • Brain glucose extraction
  • Brain ketone extraction
  • Brain lactate extraction
  • Increased brain glucose extraction in response to intra-nasal insulin administration

Hypothesis:

  1. Fasting and high-intensity exercise will increase the brain's release of BDNF and sAPPA, and these responses will be the same when ketones and lactate are passively infused into circulation in the fed and rested state.
  2. Fasting will increase brain ketone metabolism beyond that achieved when ketones are passively infused into circulation in the fed state.
  3. High-intensity exercise will increase brain lactate metabolism beyond that achieved when lactate is passively infused into circulation in the rested state.
  4. High-intensity exercise will improve the brain's insulin sensitivity to glucose, as shown by increase brain glucose uptake in response to intra-nasal insulin.

Design

This will be a repeated-measures cross-over design with participants completing two conditions separated by 4-6 weeks:

  1. Fed exercise and passive infusions of lactate and ketones
  2. 72-hr fasted exercise and passive infusions of lactate and ketones

On both visits, participants will be instrumented with arterial (radial) and venous (internal jugular) catheters to quantify cerebral oxidative and substrate (glucose, ketones, lactate) metabolism in response to: 1) fasting, 2) 6 minutes of high-intensity exercise, 3) a passive graded infusion of ketones (to mimic fasting); and 4) a passive graded infusion of lactate (to mimic exercise). Brain insulin sensitivity to glucose will be quantified in the fed and fasted states before and after exercise by a one-time dose of intranasal insulin. In the fed and fasted states at rest, a cerebrospinal fluid sample will be collected from the lumbar spine to quantify metabolomics and the production and release of neurotrophic factors (BDNF and sAPPa) from the brain.

Trial Sites All testing will take place in the ARTs Building (Room 184) in the Centre for Heart, Lung and Vascular Health research laboratory in Kelowna, British Columbia, Canada.

Participants Sample size The investigators will collect data in 12 subjects with both sexes included. A sample size calculation (power >0.8, significance \< 0.05) based on our preliminary data indicates 8 participants are required; the investigators will aim to recruit 12 volunteers of both sexes to better represent the population, not to investigate sex differences. Written, informed consent will be obtained from participants. The investigators anticipate a dropout rate of \<5%.

Inclusion criteria

  • Aged 19 - 40 years old
  • Regularly physically active, as determined via questionnaires

Exclusion criteria

  • Current smokers
  • Acute bronchial asthma, chronic obstructive airway or status asthmaticus
  • Obese (body mass index greater than 30 kg m-2)
  • Requiring daily prescription medications that may affect responses to exercise, e.g., anti-hypertensives, anti-arrhythmogenics, inhalers
  • History of disease/dysfunction that could cause complication with exercise, e.g. cardiovascular, respiratory, neurological or musculoskeletal diseases
  • Irregular or absent menstrual cycle (females)
  • Pregnant or may suspect pregnancy, or post-menopausal (females)
  • Any unexpected adverse responses to pre-experimental exercise tests
  • Any contraindication to a lumbar subarachnoid access

Screening/Baseline Evaluation

The above inclusion and exclusion criteria will be examined via a health screening questionnaire and a clinical screening performed by a physician. This screening will include:

  • Resting blood pressure,
  • 12-lead electrocardiogram,
  • Cardiopulmonary exercise testing,
  • Fasting blood glucose.

Discontinuation criteria

  • Any adverse response to invasive procedures, i.e., catheterization and cerebrospinal fluid sampling (please see Risks below)

In addition to the above and as per UBC Clinical Research Ethics Board guidelines, all research participants are able to withdraw from the study at any time and without reason.

Experimental procedures

Participants will visit the lab on two occasions. Details of the experimental visits are outlined below:

  1. Fed exercise and passive infusions of lactate and ketones

    Participants will arrive to the lab 1 hr after eating a light meal of their choice. Participants will lie on a bed and will be instrumented with indwelling radial artery and internal jugular vein catheters. One hour after catheterizations, cerebral blood flow will be measured non-invasively by Duplex ultrasound of the internal carotid and vertebral arteries. Blood samples will be collected from the arterial and venous circulations for resting measures of brain oxidative and substrate (glucose, ketones and lactate) metabolism. A single cerebrospinal fluid sample will be collected from the lumbar spine between L4 and L5. This procedure will be performed by a highly trained physician who uses these techniques routinely for patient care on a near daily basis. Thereafter, the primary ketone, beta-hydroxybutyrate (Bhb), will be infused via an antecubital (arm) vein in a stepwise manner to induce circulating concentrations of 1, 3 and 5 mmol/L. Following a complete recovery, i.e., Bhb concentration return to resting values, intravenous lactate will be infused in a stepwise manner to induce circulating concentrations of 5, 10 and 15 mmol/L. Following a complete recovery of blood lactate levels, an intravenous combined infusion (Bhb and lactate) will be administered to induce circulating concentrations of 3 and 10 mmol/L, respectively. Participants will then be given a light standardized meal and 1 hour to rest and digest. Lastly, participants will self-administer a single-dose of intranasal insulin before and after completing 6-minutes of high-intensity cycling intervals. After the final dose of intranasal insulin, participants will be de-instrumented marking the end of the visit. The total time for this visit is estimated to be 3-4 hours.

  2. 72-hr fasted exercise and passive infusions of lactate and ketones

This visit is identical to condition 1, except that participants will arrive at the lab 72 hr fasted and will not be provided with a light meal until completion of all experimental procedures. Prior to initiating the fast, participants will be equipped with a continuous glucose monitor so that the researchers can track their blood glucose during the fast. As such, the total time for this visit is also estimated to be 3-4 hours.

High-intensity exercise protocol. Participants will complete six 40-s bouts of cycling at a work rate that elicits 100% maximal aerobic power (V̇O2max) followed by 20 s of active recovery at 25% VO2max. The investigators have shown this exercise bout to increase lactate >5-fold in both the fed and fasted state.

Randomization of conditions. The order of conditions, i.e., fed or fasted, will be randomized. It is impossible to blind the participants to the fed and fasted conditions since fasting requires abstaining for eating prior to visiting the lab. Researchers will not be blinded because they will be monitoring the subjects while they are fasting prior to visiting the lab.

02

Conditions studied

  • Metabolic Diseases
  • Aging Problems

Browse trials for

Keywords

  • brain
  • BDNF
  • metabolism
  • ketones
  • lactate
03

In context

Metabolic Diseases

997 studies on the registry are indexed under Metabolic Diseases; 234 are open to participants now.

This study's planned enrollment of 12 is below the median of 48 across 670 interventional studies indexed under Metabolic Diseases.

Browse Metabolic Diseases studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Regularly physically active, as determined via questionnaires

Exclusion criteria

Exclusion Criteria:

  • Current smokers
  • Acute bronchial asthma, chronic obstructive airway or status asthmaticus
  • Obese (body mass index greater than 30 kg m-2)
  • Requiring daily prescription medications that may affect responses to exercise, e.g., anti-hypertensives, anti-arrhythmogenics, inhalers
  • History of disease/dysfunction that could cause complication with exercise, e.g. cardiovascular, respiratory, neurological or musculoskeletal diseases
  • Irregular or absent menstrual cycle (females)
  • Pregnant or may suspect pregnancy, or post-menopausal (females)
  • Any unexpected adverse responses to pre-experimental exercise tests
  • Any contraindication to a lumbar subarachnoid access
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Fed

    Exercise and passive infusions of ketones and lactate in the fed state. Participants will be fed a small meal in the middle of the protocol, also.

    Other: Fed

  • Experimental
    Fasted

    Exercise and passive infusions of ketones and lactate in the fasted state. Participants will be required to fast for 72 hours prior to arriving to the lab for this testing arm.

    Other: Fasted

Interventions

  • OtherFed

    Participants will eat a light meal prior to testing and be fed a light meal during testing.

  • OtherFasted

    Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.

06

What researchers measure

Primary outcomes

  1. Brain-derived neurotrophic factor, secreted amyloid beta precursor protein

    Biomarker to index neuroplasticity and resilience

    Time frame: Data collected at rest, during graded infusions of lactate and ketones, pre- and post- 6 minutes of high-intensity cycling exercise

Secondary outcomes

  1. Brain substrate metabolism

    The brain's turnover of glucose, beta-hydroxybutyrate (ketone body) and lactate

    Time frame: Data collected at rest, during graded infusions of lactate and ketones, pre- and post- 6 minutes of high-intensity cycling exercise

07

Study locations

1 site
  • University of British Columbia - Okanagan Campus
    Kelowna, British Columbia V1V1V7, Canada
08

References and documents

Individual participant data

Plan to share: No — No personal data will be made available publicly or to other researchers.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06000605
Lead sponsor
University of British Columbia
Collaborators
University of Otago
Responsible party
Phil Ainslie (Professor, University of British Columbia) — Principal investigator
First posted
Aug 21, 2023
Start date
Oct 1, 2023 (estimated)
Primary completion
Jan 1, 2024 (estimated)
Completion
Jan 1, 2024 (estimated)
Last update
Aug 24, 2023

Study contacts

Travis D Gibbons, PhD
Contact
travis.gibbons@ubc.ca
7785836976
Philip N Ainslie, PhD
Contact
phil.ainslie@ubc.ca
2508078089

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion